Ogsiveo Side Effects

Generic name: nirogacestat

Medically reviewed by Drugs.com. Last updated on Aug 6, 2024.

Note: This document provides detailed information about Ogsiveo.

Applies to nirogacestat: oral tablets Side Effects associated with nirogacestat. Some dosage forms listed on this page may not apply specifically to the brand name Ogsiveo.

Applies to nirogacestat: oral tablets.

Side effects include:

Most common adverse reactions (incidence ≥15%): diarrhea, ovarian toxicity, rash, nausea, fatigue, stomatitis, headache, abdominal pain, cough, alopecia, upper respiratory tract infection, dyspnea.

For healthcare professionals

Applies to nirogacestat: oral tablet.

General adverse events

The most common reactions/laboratory abnormalities occurring in 15% of patients or greater included diarrhea, ovarian toxicity, rash, nausea, fatigue, stomatitis, headache, abdominal pain, cough, alopecia, upper respiratory tract infection, dyspnea, decreased phosphate, increased urine glucose, increased urine protein, increased AST, increased ALT, and decreased potassium.^[Ref]

Dermatologic

• Very common (10% or more): Rash (68%), alopecia (19%)
• Frequency not reported: Hidradenitis suppurativa, folliculitis

Endocrine

• Very common (10% or more): Ovarian toxicity (75%)

Ovarian toxicity included ovarian failure, premature menopause, amenorrhea, and menopause.

Gastrointestinal

• Very common (10% or more): Diarrhea (84%), nausea (54%), stomatitis (39%), abdominal pain (22%)

Hepatic

• Very common (10% or more): Increased aspartate aminotransferase (33%), increased alanine aminotransferase (30%)

Metabolic

• Very common (10% or more): Decreased phosphate (65%), decreased potassium (22%)

Oncologic

• Frequency not reported: Non-melanoma skin cancers

Other

• Very common (10% or more): Fatigue (54%)
• Frequency not reported: Influenza-like illness

Renal

• Very common (10% or more): Increased urine glucose (51%), increased urine protein (40%)

Respiratory

• Very common (10% or more): Cough (20%), upper respiratory tract infection (17%), dyspnea (16%)
• Frequency not reported: Epistaxis

Nervous system

• Very common (10% or more): Headache (30%)

Further information

Ogsiveo side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer